Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.